| Literature DB >> 35740203 |
Noor Ul Islam1, Muhammad Naveed Umar1, Ezzat Khan1,2, Fakhria A Al-Joufi3, Shaymaa Najm Abed4, Muhammad Said1, Habib Ullah5, Muhammad Iftikhar6, Muhammad Zahoor6, Farhat Ali Khan7.
Abstract
To overcome the issue of multidrug resistant (MDR) microbes, the exploration of ways to improve the antimicrobial efficiency of existing antibiotics is one of the promising approaches. In search of synthons with higher efficiency, in current investigations, cocrystal and amorphous salt of levofloxacin hemihydrate (LEV) were developed with phthalimide (PTH) and caffeic acid (CFA). New materials were characterized with the help of FT-IR, Raman spectroscopy, powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). Shifting, attenuation, appearance/disappearance and broadening of bands were observed in the FT-IR and Raman spectra of the materials as evidence of the required product. The PXRD diffraction pattern observed for LEV-PTH indicated cocrystal while halo diffractogram of LEV-CFA revealed amorphous nature. DSC/TG analysis confirmed the hydrated nature of the cocrystal/salt. The dissolution rate and antimicrobial activity against selected strains, K.pneumonia, E. coli and S. typhi of parent drug and the new material were compared. The zone of inhibition (ZI) observed for 5 µg LEV-PTH was 30.4 + 0.36 (K. pneumonia), 26.33 + 0.35 (E. coli) and 30.03 + 0.25 mm (S. typhi) while LEV-CFA salt (5 µg) against the same strains inhibited 33.96 ± 0.25, 31.66 ± 0.35 and 27.93 ± 0.40 mm, respectively. These novel formulations enhance the dissolution rate as well as antibacterial efficiency and are expected to be potent against MDR bacterial strains.Entities:
Keywords: MDR strains; antibacterial activity; heterosynthons; levofloxacin/caffeic acid; levofloxacin/phthalimide
Year: 2022 PMID: 35740203 PMCID: PMC9220774 DOI: 10.3390/antibiotics11060797
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1Chemical structures of LEV (a), CFA (b), and PTH (c).
Melting point of raw materials and cocrystal.
| Sample | Melting Point (°C) |
|---|---|
| Levofloxacin | 224–226 |
| phthalimide | 234–236 |
| Caffiec acid | 220–224 |
| Cocrystal (LEV-PTH) | 172–176 |
| Salt (LEV-CFA) | 150–152 |
Figure 2FTIR spectra of cocrystals (LEV-PTH) and amorphous salt (LEV-CFA) and respective pure components wave number (4000–500 cm−1).
Figure 3Raman spectra of cocrystal (LEV-PTH), amorphous salt (LEV-CFA) and respective pure components wave number range (200–1800 cm−1).
Figure 4PXRD diffractograms of cocrystal (LEV-PTH), amorphous salt (LEV-CFA) and respective pure components.
Figure 5DSC thermograms of cocrystal (LEV-PTH), amorphous salt (LEV-CFA) and their respective pure components.
Figure 6Powder dissolution profile of LEV, cocrystal (LEV-PTH) and amorphous salt (LEV-CFA) in dissolution mediums phosphate buffer pH 6.8 (a) and 0.1 mM HCl (b).
Zone of inhibition values of LEV, cocrystal and amorphous salt against different bacterial strains.
| Bacterial Strain | Sample Amount (µg) | LEV | LEV-PTH Cocrystal (71%) Zone of Inhibition (mm) | LEV-CFA Amorphous Salt (66.7%) |
|---|---|---|---|---|
|
| 5 | 28.16 ± 0.76 | 30.4 ± 0.36 | 33.96 ± 0.25 |
| 2.5 | 23.33 ± 0.57 | 24.16 ± 0.47 | 28.30 ± 0.26 | |
| 1.25 | 17.63 ± 0.77 | 19.93 ± 0.60 | 21.76 ± 0.25 | |
| 0.62 | 12.26 ± 0.30 | 14.36 ± 0.35 | 18.00 ± 0.30 | |
|
| 5 | 25.033 ± 0.25 | 26.33 ± 0.35 | 31.66 ± 0.35 |
| 2.5 | 18.13 ± 0.32 | 21.3 ± 0.30 | 26.23 ± 0.25 | |
| 1.25 | 14.36 ± 0.40 | 15.43 ± 45 | 21.30 ± 0.30 | |
| 0.62 | 12.3 ± 0.26 | 14.03 ± 15 | 18.23 ± 0.20 | |
|
| 5 | 27.03 ± 0.65 | 30.03 ± 0.25 | 32.80 ± 0.20 |
| 2.5 | 22.16 ± 0.37 | 22.93 ± 0.50 | 27.93 ± 0.40 | |
| 1.25 | 17.96 ± 0.15 | 19.30 ± 30 | 22.73 ± 0.25 | |
| 0.62 | 11.06 ± 0.20 | 14.26 ± 25 | 17.03 ± 0.25 |
Percent concentration of active antibiotic in the formulations present in the bracket in first row of column two, three and four of the table.
MIC values of pure LEV, cocrystal and amorphous salt against different bacterial strains.
| Sample | MIC (μg/mL) | ||
|---|---|---|---|
|
|
|
| |
| Pure LEV (100%) | 32 | 128 | 64 |
| LEV-PTH cocrystal (71%) | 16 | 64 | 32 |
| LEV-CFA salt (66.7%) | 16 | 16 | 16 |
In the bracket in first column of the table is percent concentration of active antibiotic in the formulations.